Exisulind

Summary

Exisulind (CHEMBL488025) is a phase-3 clinical-stage small-molecule cyclooxygenase 2 inhibitor; indicated across 7 conditions including non-small cell lung carcinoma and prostate adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 11
• Chemistry: 372.4 Da · C20H17FO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL488025
Name	Exisulind
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5472495
ChEBI	CHEBI:64212
Molecular formula	C20H17FO4S
Molecular weight	372.4
InChIKey	MVGSNCBCUWPVDA-MFOYZWKCSA-N

SMILES: CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O

IUPAC name: 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfonylphenyl)methylidene]inden-1-yl]acetic acid

ChEBI definition: A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.

Pharmacological roles (ChEBI): cyclooxygenase 2 inhibitor, EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor, apoptosis inducer.

Also known as: Aptosyn, Exisulind, FGN-1, Prevatec, Sulindac related compound b, Sulindac sulfone, Sulindac sulphone, sulindac sulfone, SID11111778, SID50107023, SID56463018, SID85231220

Patent coverage: 121 distinct patent families (241 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 155 (64%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Peripheral myelin protein 22, Thyrotropin receptor, Endothelin-1 receptor, Alpha-galactosidase A, Aldo-keto reductase family 1 member B1, Muscarinic acetylcholine receptor M1, Cytochrome P450 1A2, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08482	7.05	Potency	89.1	nM	CHEMBL_ACT_4799533
TDP1	6.6	Potency	251.2	nM	CHEMBL_ACT_3934707
P07943	6.57	IC50	269	nM	CHEMBL_ACT_7805938
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_3925557
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_4620107
EDNRA	5.22	Ki	6064	nM	CHEMBL_ACT_7807997
MAPT	5.05	Potency	8912	nM	CHEMBL_ACT_4013291
EDNRA	5.01	IC50	9853	nM	CHEMBL_ACT_7807996
GLA	5	Potency	10000	nM	CHEMBL_ACT_4876781

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
lung neoplasm	2	MONDO:0021117	MONDO:0008903
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
breast neoplasm	1	MONDO:0021100	EFO:0003869

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	7
PHASE1/PHASE2	2
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00026468	PHASE2/PHASE3	WITHDRAWN	Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
NCT00085826	PHASE3	COMPLETED	A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
NCT00037609	PHASE1/PHASE2	COMPLETED	Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
NCT00041054	PHASE2	COMPLETED	Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00041314	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00052845	PHASE2	COMPLETED	Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00072618	PHASE1/PHASE2	COMPLETED	Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00078910	PHASE2	COMPLETED	Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
NCT00166426	PHASE2	COMPLETED	Exisulind Versus Placebo After Surgical Removal of the Prostate
NCT00166478	PHASE2	COMPLETED	Exisulind Prior to Radical Prostatectomy
NCT00283803	PHASE2	COMPLETED	Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).